Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Ho

Vascular & Interventional Radiology Lewiston, ID Medical Doctor

NPI 1023096955 CMS profile 227342

415 6Th St, Lewiston, ID 83501

Open in the dashboard

General payments

$10,061

202 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Ho of Lewiston, ID is reported in the CMS Open Payments database as having received $10,061 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,035 49
2024 General $1,180 26
2023 General $1,128 30
2022 General $1,894 29
2021 General $576 24
2020 General $1,157 22
2019 General $1,091 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Ho
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to John Ho were reported at $3,035. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year John Ho Vascular & Interventional Radiology median Middle half National median
2019 $1,091 $422 $125–$1,555 $163
2020 $1,157 $200 $68–$652 $114
2021 $576 $280 $99–$866 $132
2022 $1,894 $433 $137–$1,497 $149
2023 $1,128 $506 $152–$2,019 $160
2024 $1,180 $556 $175–$1,930 $164
2025 $3,035 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $3,409 83 payments
  2. Medtronic, Inc. $1,521 15 payments
  3. Silk Road Medical, Inc. $1,082 15 payments
  4. Medtronic Vascular, Inc. $714 8 payments
  5. MicroVention, Inc. $608 4 payments
  6. Endologix, Inc. $511 2 payments
  7. Boston Scientific Corporation $318 13 payments
  8. Shockwave Medical, Inc $263 9 payments
  9. Stryker Corporation $257 3 payments
  10. DePuy Synthes Sales Inc. $243 10 payments
  11. Other $1,135 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,744 182 payments
  2. Travel and Lodging $3,529 18 payments
  3. Consulting Fee $788 2 payments
Products named General payments · program years 2019–2025
  1. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $1,455 15 payments
  2. RIST $1,361 9 payments
  3. ENROUTE Transcarotid Stent $1,082 15 payments
  4. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,082 15 payments
  5. VenaSeal $714 8 payments
  6. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $584 6 payments
  7. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $584 6 payments
  8. WEB $584 3 payments
  9. ENDOCROSS Device $511 2 payments
  10. Torus Stent Graft System $511 2 payments
  11. Other $4,608 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,354

Median for Interventional Radiology: 38

Drug cost

$194,857

Median for Interventional Radiology: $333

Branded share of claims

56.2%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 171 $177,048
Clopidogrel Clopidogrel Bisulfate Brand 564 $6,732
Pregabalin Generic 103 $2,971
Cilostazol Generic 89 $2,120
Enoxaparin Sodium Generic 18 $1,613
Gabapentin Generic 72 $787
Potassium Chloride Generic 34 $624
Nifedipine Er Nifedipine Brand 26 $476
Amlodipine Besylate Generic 63 $413
Spironolactone Generic 38 $383

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 146 billing codes

Paid by Medicare

$297,927

Medicare's payments for the services billed

Medicare patients

898

Average age 76

Services billed

3,331

413 women, 485 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 41%
Ischemic heart disease 36%
Chronic kidney disease 35%
COPD 31%
Heart failure 27%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record